Initiate a third cohort in the U.S. Phase I/II clinical trial
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 17 Dec 2021
- Due
- 31 Dec 2022
- Delivered
- by 1 Jun 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“uniQure also plans to initiate a third cohort in the ongoing U.S. Phase I/II clinical trial in the second half of 2022”
What we found
Evidence strength B What the grades mean
uniQure initiated a third cohort in the U.S. Phase I/II clinical trial, but in 2023 rather than the second half of 2022 as committed.
-
B uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
“In the second half of 2023, uniQure expects to initiate a third cohort in the ongoing U.S. clinical trial to further investigate both doses in combination with perioperative immunosuppression.”
-
B uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease
“uniQure began enrolling patients in a third cohort to further investigate both doses in combination with perioperative immune suppression with a focus on evaluating near-term safety.”
-
B Phase I/II Clinical Trial of AMT-130
“In February 2025, we completed enrollment in a third cohort investigating an optimized immunosuppression regimen.” ✓ confirmed on the page
Checked 3 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +365 days
- 2 versions
-
Version 1 · original · stated 17 Dec 2021
Deadline 31 Dec 2022 (“second half of 2022”) · wording expected
-
Version 2 · stated 22 Jun 2023
Deadline 31 Dec 2023 (“In the second half of 2023”) · wording expected
“In the second half of 2023, uniQure expects to initiate a third cohort in the ongoing U.S. clinical trial”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- third cohort in the U.S. Phase I/II clinical trial
- Where
- United States
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-QURE-001789 · Corrections policy